Linzagolix is ​​a ‘win-win’ for patients with uterine fibroids

Linzagolix is ​​a ‘win-win’ for patients with uterine fibroids

Source/Disclosures

source: Healio Interviews

Disclosures: Bradley reports no relevant financial disclosures.


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN DIEGO — Several abstracts were presented at the ACOG Annual Clinical & Scientific Meeting on the efficacy and safety of linzagolix, an investigational oral GnRH antagonist being developed for the treatment of fibroid-related symptoms.

in this video, Linda BradleyMD, a professor of OB/GYN and reproductive biology at the Cleveland Clinic and the medical director of the American Association of Gynecologic Laparoscopists, discusses the results from the randomized, double-blind, placebo-controlled phase 3 trials PRIMROSE 1 and PRIMROSE 2.

“I think this is going to be a win-win for our patients, to be able to offer them new doses with and without add-back therapy, and these patients can have improvement in their quality of life with safety, efficacy and a well -designed clinical trial to show that this is a new drug — investigational right now — that we hope will be able to be approved,” Bradley said.

References:

  • Al-Hendy A, et al. Abstract 104. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.
  • Al-Hendy A, et al. Abstract 107. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.
  • Marsh EE, et al. Abstract 106. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.
  • Stewart EA, et al. Abstract 105. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.
  • Taylor HS, et al. Abstract 108. Presented at: ACOG Annual Clinical & Scientific Meeting; May 6-8, 2022; San Diego.

Leave a Comment

Your email address will not be published.